EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial

Uwe Platzbecker iD, Lionel Adès, Pau Montesinos iD, Emanuele Ammatuna iD, Pierre Fenaux, Claudia Baldus, Massimo Bernardi iD, Céline Berthon iD, Monica Bocchia iD, Caroline Bonmati, Erika Borlenghi iD, Martin Bornhäuser iD und 38 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-25-00535 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Uwe Platzbecker und 49 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Carl Gustav Carus and TU Dresden - Faculty of Medicine, Medical Clinic 1, Dresden, Germany. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Tretinoin. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The phase III APOLLO trial prospectively compared the efficacy of arsenic trioxide (ATO) in combination with all-trans retinoic acid (ATRA) regimen (ATRA and ATO [ATRA-ATO]) plus low-dose idarubicin versus standard ATRA plus anthracycline-based chemotherapy (ATRA-CHT) regimen (ie, ATRA and idarubicin regimen) in patients with high-risk acute promyelocytic leukemia (APL; EudraCT 2015-01151-68; ClinicalTrials.gov identifier: NCT02688140 ). METHODS Adult patients with newly diagnosed high-risk APL in the ATRA-ATO arm received ATO 0.15 mg/kg once daily and ATRA 45 mg/m 2 twice daily until complete remission (CR), with two doses of idarubicin 12 mg/m 2 on days 1 and 3, followed by consolidation therapy (four ATRA-ATO cycles). Patients in the ATRA-CHT arm received induction with ATRA 45 mg/m 2 twice daily and idarubicin 12 mg/m 2 once daily on days 1, 3, 5, and 7, followed by three cycles of chemotherapy-based consolidation and 2 years of maintenance therapy. The primary study end point was event-free survival (EFS) at 2 years. RESULTS As of July 2022, 133 eligible patients had received either ATRA-ATO (n = 68) or ATRA-CHT (n = 65). The study was discontinued prematurely because of slow accrual during the COVID-19 pandemic. After a median follow-up of 37 months (range, 1.7-88.6 months), 2-year EFS was 88% in the ATRA-ATO arm and 71% in the ATRA-CHT arm (HR, 0.4 [95% CI, 0.17 to 0.92]; log-rank test P = .02). At a median of 7.8 and 12.1 months from achievement of CR, molecular relapse occurred in one (1.5%) ATRA-ATO patient versus eight (12.3%) ATRA-CHT patients ( P = .014). Overall, 32% and 68% of patients receiving ATRA-ATO and ATRA-CHT, respectively, reported serious treatment-emergent adverse events ( P < .01). CONCLUSION The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsArsenic TrioxideLeukemia, Promyelocytic, AcuteTretinoinAdultAgedFemaleHumansMaleMiddle AgedYoung AdultIdarubicinProspective Studies

Substanzen

Arsenic TrioxideIdarubicinTretinoin

Autor:innen und Institutionen

  • University Hospital Carl Gustav Carus and TU Dresden - Faculty of Medicine, Medical Clinic 1, Dresden, Germany.
  • Service d'Hématologie Séniors, Assistance Publique hôpitaux de Paris, Paris Saint-Louis Leukemia Institute France, Hôpital Saint Louis, Paris, France.
  • Université Paris Cité, Paris, France.
  • Servicio de Hematología, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
  • Afd. Hematologie, University Medical Center Groningen, Groningen, the Netherlands.
  • Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany.

ORCID-Profile: Uwe Platzbecker, Pau Montesinos, Emanuele Ammatuna, Massimo Bernardi, Céline Berthon, Monica Bocchia, Erika Borlenghi, Martin Bornhäuser, Sylvain Chantepie, Jordi Esteve Reyner, Luca Guarnera, Maël Heiblig, Alwin Johannes Krämer, Marie-Pierre Ledoux, Valentina Mancini, Klaus Metzeler, Maria Cristina Miggiano, Carsten Müller-Tidow, Pierre Peterlin, Kathrin Rieger, Christoph Röllig, Giovanni Rossi, Hubert Serve, Emmanuelle Tavernier-Tardy, Christian Thiede, Patrizia Zappasodi, Maria Teresa Voso

Zitieren

APA

Platzbecker, U., Adès, L., Montesinos, P., Ammatuna, E., Fenaux, P., Baldus, C., Bernardi, M., Berthon, C., Bocchia, M., Bonmati, C., Borlenghi, E., Bornhäuser, M., Carp, D., Chantepie, S., Crea, E., Divona, M., Döhner, H., Ehninger, G., Esteve Reyner, J., …, & SAL, AMCL-CG, AML-SG, OSHO, PETHEMA, HOVON and GIMEMA study groups (2025). Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00535

Vancouver

Platzbecker U, Adès L, Montesinos P, Ammatuna E, Fenaux P, Baldus C, et al. Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00535

BibTeX
@article{Platzbecker2025,
  author = {Platzbecker, Uwe and Adès, Lionel and Montesinos, Pau and Ammatuna, Emanuele and Fenaux, Pierre and Baldus, Claudia and Bernardi, Massimo and Berthon, Céline and Bocchia, Monica and Bonmati, Caroline and Borlenghi, Erika and Bornhäuser, Martin and Carp, Diana and Chantepie, Sylvain and Crea, Enrico and Divona, Mariadomenica and Döhner, Hartmut and Ehninger, Gerhard and Esteve Reyner, Jordi and Frayfer, Jamilé and Garrido Diaz, Ana and Gil, Cristina and Guarnera, Luca and Hamm, Anna Franziska and Heiblig, Maël and Heidenreich, Daniela and Krämer, Alwin Johannes and Ledoux, Marie-Pierre and Lunghi, Monia and Mancini, Valentina and Metzeler, Klaus and Miggiano, Maria Cristina and Müller-Tidow, Carsten and Peterlin, Pierre and Piciocchi, Alfonso and Rieger, Kathrin and Röllig, Christoph and Rossi, Giovanni and Sanz, Miguel A and Serve, Hubert and Söhne, Maaike and Spiekermann, Karsten and Tavernier-Tardy, Emmanuelle and Thiede, Christian and Vives Polo, Susana and Vogel, Wichard and Zappasodi, Patrizia and Ziller-Walter, Pauline and Voso, Maria Teresa and SAL, AMCL-CG, AML-SG, OSHO, PETHEMA, HOVON and GIMEMA study groups, SAL, AMCL-CG, AML-SG, OSHO, PETHEMA, HOVON and GIMEMA study groups},
  title = {Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-25-00535}
}
Kostenlos starten →